Dr. Pauza received the PhD in Molecular Biology from the University of California, Berkeley and was a postdoctoral fellow in the laboratory of Sydney Brenner, MD, Medical Research Council Laboratory of Molecular Biology in Cambridge, England. He held faculty positions at the Salk Institute for Biological Studies, La Jolla, CA, University of Wisconsin-Madison, University of Maryland Biotechnology Institute and University of Maryland, Baltimore School of Medicine where he served as Associate Director for the Institute of Human Virology and Co-Leader for the Viral Oncology Program in the Greenebaum Cancer Center. From 2016 to 2021 Dr. Pauza was Chief Science Officer for American Gene Technologies where he developed a cell and gene therapy for HIV and initiated Phase 1 studies of that product. He joined Viriom, Inc. as Chief Science Officer in 2017 and in 2021, became Chief Science Officer of Trawsfynydd Therapeutics, Inc. until it was acquired by Onconova Therapeutics in a deal that created Traws Pharma, where Dr. Pauza serves as Chief Science Officer, Virology. He holds more than 30 US patents and has more than 200 original publications in the fields of virology and cancer. Dr. Pauza is an active reviewer for many scientific journals and serves as grant reviewer for the U.S. National Institutes of Health in addition to national grant programs from 7 countries. He is actively involved in developing international scientific programs in West Africa, Europe, Russia and China, and was appointed in 2000 as the United Nations Education, Scientific and Cultural Organization Professor of Biotechnology, a position served in Rome, Italy.